Hoffmann

$NWBO Spoofing Case Update – Motion Battle The Case: Northwest Biotherapeutics, Inc v. Canaccord Genuity LLC, 1:22-cv-10185, (S.D.N.Y.) The Docket: courtlistener.com/docket/6657959… In this post we will discuss the Court’s ruling on a recent discovery related motion filed by Defendants. You can see the history of this motion from my posts in this thread: x.com/hoffmann6383/s… Essentially, the Defendants are asking $NWBO to specifically identify the spoofing orders and then limit the case to said spoofing orders. It is a very important ruling that could impact the scope of $NWBO’s claims, and thus their damages. Here is what the Defendants are asking for: "The Court should order NWBO to provide—within seven days and for all Spoofing Episodes that survived the motion to dismiss—the same color-coded, calculation-explained identification it provided in its Appendix. Consistent with Judge Schofield’s order in Harrington, NWBO should further be limited to using only the identified orders at summary judgment and trial." Last week, the Defendants’ Motion was DENIED. This is a big win for $NWBO. $NWBO already provided the Defendants the trading data. The Court is telling Defendants they have to analyze the raw data themselves and not depend on $NWBO to do that for them. There is one small caveat: “If, as, and when Defendants are unable to reconcile their own calculations with the allegations of the SAC with respect to a particular Spoofing Episode based on the methodology NWBO has explained, Defendants may bring the issue to NWBO’s attention and ask NWBO to identify how the particular calculation(s) were derived. The Court hereby orders NWBO to provide such identifications to Defendants upon request.” This ruling was a big win for $NWBO. We lost the first round of this motion battle, but won the second round. Discovery goes on!

As of this posting, the House of Commons meeting is at "Update on Standards in Public Life". The "Debate on a motion on increasing survival rates on brain tumours" is upcoming. The live stream can be followed here: parliamentlive.tv/event/index/e3… #gbm #glioblastoma $nwbo #dcvax

Spoofing Case Update - $NWBO v. Citadel, et al Case No.: 1:22-cv-10185 Docket: courtlistener.com/docket/6657959… Today we saw a letter filing by $NWBO asking for all the case management deadlines to be extended by 120 days. $NWBO's counsel blames the substitution of counsel, Les Goldman's passing, delay tactics by Defendants, among other things. I've attached an image of $NWBO's proposed deadlines. The Defendants do not consent to the extension of deadlines. Some interesting points in today's letter: ➡️Current Document Production "NWBio has so far produced 3,056 documents. Defendants have produced far less. Defendant G1 Execution Services LLC has only produced 10 documents, Defendant Virtu Americas LLC produced 26 documents, and Defendant Citadel Securities LLC produced 132 documents. The other Defendants—Canaccord Genuity LLC, GTS Securities LLC, Instinet LLC, and Lime Trading Corp.—have produced no documents at all." ➡️Nonparty Subpoenas "There have also been delays in receiving productions from nonparties. For example, in June 2025, NWBio served subpoenas to Depository Trust & Clearing Corporation (“DTCC”) and Financial Industry Regulatory Authority, Inc. (“FINRA”)—both of which are critical sources of relevant information concerning the trades at issue. Following NWBio’s persistent inquiries, DTCC only recently produced documents and FINRA is still gathering documents for future production, with partial production anticipated by mid-January and an uncertain timeline to complete production of archived data. Based on information gleaned from DTCC’s production, NWBio served additional follow-up requests to Defendants, for which responses are due today. Moreover, in October 2025, NWBio served a subpoena to nonparty OTC Link LLC, the scope of production for which is still being negotiated. All of the foregoing documents are critical to NWBio’s prosecution of this case."